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Background: To describe the rationale and design of the Northern Finland Birth Cohort (NFBC) Eye Study.
Methods: The NFBC Eye Study is a randomised prospective cohort study. The original NFBC study population
consists of 12058 subjects born in the region of Lapland and the Province of Oulu. A postal questionnaire covering
extensively the medical and socioeconomical background was sent to the 10300 subjects of the NFBC alive and
residing in Finland. For the NFBC eye study the subjects were randomised to the screening group (50%) and the
control group (50%). The screening protocol includes the following tests: automated and manifest refraction, best
corrected visual acuity, central corneal thickness, intraocular pressure, Humphrey 24–2 perimetry, stereoscopic optic
nerve head (ONH) and retinal nerve fibre layer (RNFL) photography and imaging with Scanning Laser
Ophthalmoscopy (HRT), Scanning Laser Polarimetry (GDx) and Optical Coherence Tomography (OCT).
Two ophthalmologists evaluate the ONH and RNFL photographs and the visual fields independently. All suspected
glaucoma cases are re-evaluated by two independent glaucoma experts. HRT, GDx and OCT findings are assessed
separately. In the future, both groups (100%) will be examined. The effectiveness and the cost-effectiveness of
glaucoma screening will be calculated. The response rate of the questionnaire was 67% (n = 6855) and 871
randomised subjects had undergone the eye screening protocol by the end of April 2013.
Discussion: The trial is designed to address the following questions: what is the best combination of diagnostic
tests for detecting glaucoma in an unscreened population, what are the benefits and disadvantages of the
screening to the individual and the society and is glaucoma screening both effective and cost-effective. The
prevalence, incidence and risk factors of glaucoma and other eye diseases will be evaluated, as well as their impact
on quality of life.
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Open angle glaucoma (OAG) is a major cause of avoid-
able blindness worldwide. Due to its insidious nature
and irreversible consequences, OAG is considered to ful-
fil the criteria for population screening. However, there
are no randomised controlled trials that demonstrate the
effectiveness of screening for preventing blindness from
OAG [1-3].
OAG is the most common type of glaucoma with a
prevalence of 1.5-2% in the Caucasian population aged
over 50. The worldwide number of OAG patients is* Correspondence: ville.saarela@oulu.fi
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reproduction in any medium, provided the orestimated to be 61 million and approximately 6.7 million
of them are bilaterally blind due to glaucoma [4]. The
onset and progression of the chronic optic neuropathy
due to OAG is asymptomatic until the late phase of the
disease when central vision is also affected. The progres-
sion rate of OAG varies, but it has been estimated to
take a mean time of 23 years without treatment and
35 years with treatment to progress from mild visual
field (VF) damage to at least unilateral blindness [1]. Still
up to 5% of the patients with newly diagnosed OAG are
blind in at least one eye [5]. A retrospective study in
Finland revealed the cumulative incidence of unilateral
blindness to be 6% at five years, 9% at 10 years and 15%
at 15 years after glaucoma diagnosis. Risk factors for
impending blindness were advanced stage of the diseaseLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Saarela et al. BMC Ophthalmology 2013, 13:51 Page 2 of 7
http://www.biomedcentral.com/1471-2415/13/51at diagnosis, pseudoexfoliation syndrome, poor compli-
ance and fluctuation of intraocular pressure [6]. As for
the risk factors of OAG itself, increasing age, elevated
IOP, family history of glaucoma, pseudoexfoliation syn-
drome, myopia and African origin have been identified
so far [7].
To date there is no systematic glaucoma screening in
any country and most glaucoma cases are diagnosed by
chance. Epidemiological studies have shown that at least
half of the glaucoma patients are still undiagnosed [8,9].
An organized screening program could be a cost-
effective strategy in older age groups (75–79 years of
age) based on a synthetic Markov model comparing
regular screening to opportunistic case-finding [2]. How-
ever, the results were sensitive to the estimates of several
parameters, especially screening cost and specificity of
screening tests. In screening, there should be a validated
test with good sensitivity and specificity. This has been a
major problem in glaucoma screening: there is no
“golden standard” for the diagnosis and definition of the
OAG is highly subjective depending on the observer and
the set of tests. The definition of abnormality is based
on the normative data of different diagnostic elements
and the combination of them [10]. Furthermore, struc-
tural abnormalities in the optic nerve head (ONH) and
retinal nerve fiber layer (RNFL) may precede functional
defects in the visual fields. In a cross-sectional setting,
the mean correlation between the structural and func-
tional tests is only 35% (range 22-59%) [7]. In the past
decades diagnostic imaging instruments have been de-
veloped to overcome the subjectivity of the evaluations
in the diagnostics. Still it is apparent that a single test is
insufficient to find the persons with or without glau-
coma and the best combination of the tests is unknown.
In screening, a reliable protocol for the detection of true
glaucoma is more important than early detection.
The NFBC main study was set out to explore the
long-term morbidity, disease markers, spectrum of
symptoms and psychosocial wellbeing throughout the
life span. This unselected, geographically defined popula-
tion sample consists of individuals born in 1966. The
NFBC Eye Study includes three separate entities: the
diagnostics of glaucoma, the effect of screening on glau-
coma incidence and the cost-effectiveness of screening
for glaucoma and other eye diseases. The analysis for the
diagnostics is based on both cross-sectional and cohort
designs whereas the analysis for the cost-effectiveness is
based on randomised controlled design. Hence, the trial
seeks to address the following questions: (i) what is the
best combination of diagnostic tests for detecting glau-
coma in an unscreened population, (ii) what are the
benefits and disadvantages of the eye screening to the
individual and the society and (iii) is glaucoma screening
both effective and cost-effective. Other eye diseases aswell as related factors, e.g. retinal perfusion parameters,
diabetic retinopathy, early changes related to macular
degeneration, presbyopia and vision associated quality of
life, are also assessed. Also the relationship between
birth weight and growth patterns during early life to eye
diseases is evaluated. The purpose of the NFBC Eye
Study is to evaluate the diagnostic methods and cost-
effectiveness of glaucoma screening as well as other ocu-
lar morbidity in middle-aged Caucasian population.
Methods
The NFBC main study
The original cohort consists of 12058 subjects born in
the region of Lapland and the Province of Oulu (96% of
the deliveries in these regions). The cohort is comprised
of males and females in approximately equal proportions
(Figure 1). The mothers of the subjects were recruited to
the study on the basis of the expected birth date in
1966. This unique cohort has been followed prospect-
ively since the 24th gestational week. The course of
the delivery and neonatal outcome has been confirmed
from the patient records. The original data has been
supplemented by the information collected with postal
questionnaires and clinical examinations carried out at
the age of 1, 14 and 31 years. In the previous NFBC ana-
lysis during 1997–1998 the response rate to the ques-
tionnaire was 75% [11]. Furthermore, data on morbidity,
mortality and socioeconomic factors have been collected
from national registers and hospital records.
Questionnaire and clinical examinations
The postal questionnaire was sent to the 10 300 subjects
alive and residing in Finland. The questionnaire is designed
to cover extensively the medical and socioeconomical
background of the subjects. The ophthalmological portion
includes questions on both personal and family history of
eye diseases and treatment, including surgery. Information
is also gathered on visual acuity, symptoms of presbyopia,
refractive error, the use of eyeglasses and contact lenses as
well as ocular and vision-related symptoms and quality of
life, including the 15D instrument [12]. The entire cohort
attends an extensive clinical examination including physio-
logical, cardiorespiratory, orthopedic, dermatological, cog-
nitive and dental status. Comprehensive laboratory tests
are also taken.
The NFBC eye study
The NFBC Eye Study is conducted in co-operation with
the main NFBC 1966 Study. The study has received
approval from the Ethical Committee of the Northern
Ostrobothnia Hospital District. The cohort was rando-
mised to two groups: 50% undergo the eye examination
and 50% are not examined. Thus, half of the cohort
will be screened and the other half represents the
Figure 1 The NFBC Study population.
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mised to the screening arm with a former diagnosis of
glaucoma will undergo the screening protocol in order
to evaluate the accuracy of the diagnosis. The pilot study
was conducted in 2012 in order to test the study flow.
Participants of the pilot study were healthy volunteers
from the general population with a mean age of 49 years
(n = 80).Randomisation
Out of the original cohort, 460 subjects have died and
961 have moved abroad. 10300 subjects with an address
in Finland were included in the randomisation. The
participants were stratified into three categories based
on gender, age and postcode. The subjects were divided
into four age categories according to their month of
birth: January-March, April-June, July-September and
October-December. They were divided into 13 postcode
categories roughly following the regional centres of
the national mail agency Itella. All in all, there were 104
(2 × 4 × 13) strata for randomisation. Randomisation
was performed using Resampling Stats software (Resam-
pling Stats Inc., Arlington, Virginia, USA). The epidemi-
ologist responsible for the randomisation was blinded
to all other information than the factors used for
stratification.Screening
The subjects randomised to the eye screening group
(50%) undergo the examinations presented in Table 1.
The examinations are performed by experienced study
personnel (optometrist, perimetrist and photographer).
Each subject is examined only once. An ophthalmologist
will not participate in the examination of the subjects but
is available for consultation. Up to ten subjects areexamined daily, each of them requiring an average time of
65 minutes for eye screening with this comprehensive
protocol.
By the end of April 2013 the response rate of the ques-
tionnaire was 67% (n = 6855) and 871 randomised sub-
jects had undergone the eye screening protocol. The
enrolment for the clinical examination is still in pro-
gress. Informed consent has been obtained from all
subjects attending examinations.
Diagnostics of glaucoma
Visual fields
The visual field examination is performed using the
24–2 Swedish Interactive Threshold Algorithm (SITA) of
the Humphrey Field analyser II-i (Humphrey Instru-
ments, San Leandro, California). Static white-on-white
perimetry (white test points on a white background) lim-
ited to the 24 degree central area is considered to be the
current standard for detecting glaucomatous visual field
defects [7,10,13]. Numerical data e.g. reliability indices,
glaucoma hemi-field test (GHT), visual field index (VFI),
mean deviation and pattern standard deviation are
documented. Evaluation of the overall reliability and sus-
picion of glaucoma is made by two independent ophthal-
mologists. Suspicion of early glaucomatous field loss is
based on the following three parameters: reduction of
sensitivity at the minimum of three clustered points with
significance of p < 0.05 and one of them with significance
of p < 0.01 on pattern deviation map, glaucoma hemi-
field test (GHT) regarded as “borderline” or “outside
normal limits” or pattern standard deviation abnormal at
p < 0.05 level. The visual fields are considered to be reli-
able if the rate of false-positives is less than 15% and the
rate of fixation losses is less than 20%.
Stereoscopic ONH and RNFL imaging
Color and grayscale digital fundus images are obtained
with a Canon CF-60DSi Digital Mydriatic Fundus
Camera with attached Canon EOS-1Ds MK III SLR
Digital Camera (Canon Inc., Tokyo, Japan). The pupils
are dilated for imaging. The images are processed with
Adobe Photoshop CS (Adobe Systems Inc., San Jose,
CA, USA) and Neacapture software (Neagen Ltd., Oulu,
Finland). Stereoscopic ONH photography still represents
the standard for detecting glaucomatous damage and
progression of the optic disc [14]. The separate RNFL
photographs are taken with a monochromatic blue
interference filter (495 nm) using the camera de-
scribed above. The technique is a refined digital ver-
sion of a well-documented method used in the Oulu
University Hospital for more than three decades
[15,16]. The RNFL photographs are taken and
processed by an experienced photographer. The
screening evaluations of the RNFL and ONH
Table 1 The eye examinations
Examination Examiner / instrument Method / protocol Outcome measure
Autorefraction Nidek AR-360A Refraction, near add
Automated visual acuity Nidek AR-360A Snellen visual acuity
Subjective refraction Optometrist Refraction, near add
Best corrected visual acuity Optometrist LogMAR -chart LogMAR visual acuity
Automated perimetry Humphrey Field Analyser Sita standard 24-2 Glaucoma Hemifield Test, Visual Field Index,
Mean Deviation, Pattern Standard Deviation
Tonometry Icare, Goldmann Applanation
Tonometer
Intraocular pressure
Stereoscopic ONH
photography
Canon CF-60DSi (EOS-1) Gray-scale Evaluation for glaucomatous damage
RNFL photography Canon CF-60DSi (EOS-1) Grey-scale (495 nm filter) Evaluation for glaucomatous damage
Fundus photography Canon CF-60DSi (EOS-1) Colour and gray-scale
Optic nerve head OCT Cirrus 4000 Optic Disc Cube 200 × 200 Rim thickness, Rim area, Cup:disc ratio
Macular OCT Cirrus 4000 Macular Cube 512 × 128 Macular thickness
Central corneal OCT Cirrus 4000 Anterior Segment HD
Images
Central corneal thickness
Chamber angle OCT Cirrus 4000 Anterior Segment HD
Images
Angle opening distance
Pachymetry Tomey SP-3000 Central corneal thickness
Scanning laser polarimetry GDx Pro ECC RNFL-I Summary Parameters,
Nerve Fiber Indicator
Optic nerve head topography HRT3 Moorfields Regression Analysis, Glaucoma
Probability Score, Stereomeric parameters
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eral ophthalmologists.
Modern imaging technologies: HRT, GDx and OCT
The evaluation of optic nerve head topography is carried
out using the Heidelberg Retina Tomograph (Heidelberg
Engineering, Heidelberg, Germany; HRT3, image acqui-
sition software version 3.1.2a, Heyex 1.6.2.0). The HRT
explores the ONH and the adjacent retinal nerve fibre
layer at stepwise progressing depths. The stack of
captured images is used to form a three-dimensional
topography image. The stereometric optic nerve head
parameters (e.g., cup:disc area ratio and cup shape meas-
ure), the Moorfield’s regression analysis (MRA) and
Glaucoma probability score (GPS) are calculated from
the topography image [17-19]. The findings are com-
pared to normative data and evaluated for glaucomatous
damage.
Scanning laser polarimetry is carried out with the
GDxPRO with Enhanced Corneal Compensation (soft-
ware version 1.1.0; Carl Zeiss Meditec, Dublin, CA). The
RNFL polarizes light making the reflected beam proceed
in two focus planes (“birefringence”). The thickness of
the RNFL is related to the alteration of the polarized
light. The enhanced corneal compensation mode is used
to improve signal-to-noise ratio and the quality of the
image. It has been shown to improve diagnostic accuracyfor glaucomatous damage [20]. The RNFL-I summary
parameters (TSNIT, superior and inferior average, inter-
eye symmetry, and nerve fibre indicator) are evaluated.
There is evidence suggesting that RNFL micro-structures
undergo changes in orientation and density before other
structural changes become apparent [21,22].
Cirrus HD-OCT 4000 (software version 6.0.0; Carl
Zeiss Meditec) is used to obtain spectral domain optical
coherence tomography (OCT) images. Anterior Segment
HD Images (5 Line Raster) are obtained from the central
cornea and limbus to evaluate central corneal thickness
and the angle opening distances of the anterior chamber
angle. The standard Macular Cube 512 × 128 protocol is
used to evaluate macular thickness parameters and the
Optic Disc Cube 200 × 200 protocol to assess the
peripapillary ONH parameters. The ONH parameters
acquired with Cirrus HD-OCT have been shown to be
able to discriminate between normal and glaucomatous
eyes [23].
Study flow
In this study, the definition of glaucomatous damage is
based on the examinations of the ONH, RNFL and VF
and Finnish Evidence Based Guideline ‘2 out of 3 rule’.
When at least two out of three of the examinations are
found to be abnormal, glaucoma is likely [7]. IOP is doc-
umented but not included in the definition of glaucoma.
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the patients with glaucomatous damage have normal
IOP (normal tension glaucoma) and that all patients
with elevated IOP do not develop glaucomatous damage
[24,25]. The findings of the HRT, GDx and OCT exami-
nations are analysed separately in order to compare their
sensitivity and specificity to Finnish Evidence guideline
in the screening of unselected population.
Two ophthalmologists (EK and KS) evaluate the ONH
and RNFL photographs and visual fields independently.
All suspected glaucoma cases (abnormalities in ‘2 out of
3’ or ‘1 out of 3’ in case of a severe finding) found by EK
or KS or both are re-evaluated by two independent glau-
coma experts (ML and PH) to confirm the diagnosis. A
third glaucoma expert (ATu) will re-evaluate the find-
ings in case of disagreement between the two glaucoma
experts. If glaucomatous damage is identified by the im-
aging instruments (HRT, GDx, OCT) in subjects not
considered glaucoma suspects by the ophthalmologists,
they are re-evaluated by the glaucoma experts. A ran-
dom sample of subjects with normal findings is also
re-evaluated by the experts for quality control (Figure 2).
All subjects with suspected or diagnosed glaucoma are
referred to the hospital eye department for follow-up
and consideration for treatment. After 10 years’ time,
starting in 2023, the entire cohort (100%) will be exam-
ined with a similar protocol. The clinical and cost dataFigure 2 The study flow. Glaucoma is suspected by two independent ge
technology (HRT, GDx, OCT). The diagnosis is confirmed by glaucoma expeof the unscreened arm will be then collected retrospect-
ively from health care records.Statistical analyses
IBM SPSS Statistics v. 20 is used for statistical analyses.
Continuous data will be analyzed by two-tailed unpaired
t-test and categorical data by χ2 test. Frequencies and
standard deviations for the baseline characteristics and
the risk ratios for eye morbidity will be calculated. The
sensitivity and specificity of the diagnostic tests and
inter-observer agreement rate on glaucoma detection
will be assessed. Later on, the risk ratios for developing
glaucoma and visual disability in the screened and un-
screened group are compared. The cost-effectiveness of
the screening will be calculated in terms of gained
QALY’s and avoided years of visual disability [1,2]. Stat-
istical significance will be reported when p < 0.05.Discussion
The NFBC 1966 cohort is a well-documented, struc-
tured and lead cohort. It is a large cohort with more
than 10 000 subjects in follow-up. It is population-
based and very homogenous in respect to many im-
portant, potentially confounding, factors. Hence, the
results are applicable to populations with a Caucasian
ethnic origin.neral ophthalmologists (A and B) or based on the findings of imaging
rts (C, D and E).
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spectively followed since the 24th gestational week. In
addition to the glaucoma screening tests, also examina-
tions suitable for diagnosing other eye diseases are
obtained, e.g. macular OCT and fundus photography.
The prospective follow-up allows the evaluation of the
relationship between birth weight and growth patterns
during early life to eye diseases. Risk factors and their
value in predicting future glaucoma and other eye ab-
normalities will also be assessed.
The main challenge for glaucoma research is the lack
of the diagnostic reference method, i.e. the golden stand-
ard. Any single conventional or modern diagnostic test
is not reliable enough to detect a new or progressing
glaucoma on its own. To date the diagnosis and deter-
mination of stability or instability of glaucoma has been
based largely on the subjective expert opinion on struc-
tural and functional tests. The opinion between experts
still tends to vary: the range of kappa statistic strength of
agreement in different cross-sectional studies has been
0.5-0.9 [7]. From this point of view, objective imaging
tools are expected to be useful to get a more objective
evaluation of the RNFL and ONH. Still, the management
decisions should not be based solely on the results of a
single technology [26,27]. The visual fields and the im-
aging results of HRT, GDx and OCT are also subject to
fluctuation. Glaucoma is a progressive optic neuropathy
and the variability of test results disturb the detection of
progression. Progression during follow-up will be used a
reference standard for the diagnosis as progression is a
part of the definition of glaucoma [28].
Repeated testing has been shown to reduce the
variability of test results [29]. However, in a popula-
tion screening setting, it is not feasible to perform re-
peated screening tests to all subjects. In the current
study, only subjects with glaucomatous findings are
referred to hospital for treatment and follow-up. It
should be noted that this trial offers meticulous eye
examinations for glaucoma screening but not actual
treatment and care.
The effectiveness of screening can best be demon-
strated by a randomised controlled setting. To date
randomised diagnostic studies in glaucoma have been
missing [24]. To our knowledge, this study is the first
randomised controlled trial on glaucoma screening in
an unselected population. Optimal intervention and
prevention of the diseases may be possible if the
high-risk groups are detected early. It is known that
no single test is sufficient to discriminate persons
with and without glaucoma but the optimum set and
number of diagnostic tests is unknown [1]. Moreover,
a single examination of functional damage may not
be reliable and the repeated test should be done in
case of suspected damage.In 10 years’ time the entire cohort (both the screened
and the controls) will be examined with a similar screen-
ing protocol described here. The incidence of glaucoma
and other eye diseases in both groups will be evaluated
and the effectiveness and cost-effectiveness of glaucoma
screening for preventing blindness can be assessed. So
far, there has not been compatible evidence for calculat-
ing the cost-utility of glaucoma screening [1,2]. A
European multi-centre randomised screening trial has
been suggested to evaluate cost-effectiveness in preven-
ting glaucoma induced visual impairment. The NFBC
eye study is designed to provide the much needed high
quality evidence for the evaluation of the effectiveness
and cost-effectiveness of glaucoma screening.
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